Brett A Cowans from 3437 Covington St, Lafayette, IN 47906, age 66, Phone: (765)4639603

Us Patents

Polymorphs Of Zaleplon And Methods For The Preparation Thereof
view source
US Patent:

20050176735, Aug 11, 2005
Filed:

Aug 23, 2004
Appl. No.:

10/924436
Inventors:

Farhan Aslam - Edgewater NJ, US
Brett Cowans - West Lafayette IN, US
Stephen Byrn - West Lafayette IN, US
G. Stahly - West Lafayette IN, US
International Classification:

A61K031/519
C07D487/04
US Classification:

514259300, 544281000
Abstract:

This invention relates to novel crystalline polymorphic forms of zaleplon (N-[3-(3-cyanopyrazolo[1,5a]pyrimidin-7-yl)phenyl]-N-ethylacetamide), methods for the preparation thereof; and their use as anxiolytic. antiepileptic. and sedative-hypnotic agents and skeletal muscle relaxants.

Solid Forms Of 2-(2,4-Difluorophenyl)-6-(1-(2,6-Difluorophenyl)Ureido)Nicotinamide)
view source
US Patent:

20110086891, Apr 14, 2011
Filed:

Feb 12, 2010
Appl. No.:

12/705105
Inventors:

Michael Hurrey - Maynard MA, US
Dimitar Alargov - Brighton MA, US
Steven C. Johnston - Bolton MA, US
Stefanie Roeper - Cambridge MA, US
John R. Snoonian - Bolton MA, US
Brett A. Cowans - West Lafayette IN, US
Petinka Vlahova - West Lafayette IN, US
Alexander Eberlin - Cambridge, GB
Mark Eddleston - Cambridge, GB
Christopher Frampton - Suffolk, GB
Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:

A61K 31/465
C07D 213/82
A61P 29/00
A61P 19/10
US Classification:

514353, 546306
Abstract:

This invention relates to solid forms of 2-(2,4-difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide and pharmaceutical compositions thereof, and methods and uses therewith.

Polymorphs Of Zaleplon And Methods For The Preparation Thereof
view source
US Patent:

20020072527, Jun 13, 2002
Filed:

Aug 2, 2001
Appl. No.:

09/921017
Inventors:

Farhan Aslam - Edgewater NJ, US
Brett Cowans - West Lafayette IN, US
Stephen Byrn - West Lafayette IN, US
G. Stahly - West Lafayette IN, US
Assignee:

SSCI, INC.
International Classification:

A61K031/519
C07D487/04
US Classification:

514/262100, 544/262000
Abstract:

This invention relates to novel crystalline polymorphic forms of zaleplon (N-[3-(3-cyanopyrazolo[1,5a]pyrimidin-7-yl)phenyl]-N-ethylacetamide), methods for the preparation thereof, and their use as anxiolytic, antiepileptic, and sedative-hypnotic agents and skeletal muscle relaxants.

Inhibiting The Transient Receptor Potential A1 Ion Channel
view source
US Patent:

20180230149, Aug 16, 2018
Filed:

Mar 29, 2018
Appl. No.:

15/940253
Inventors:

- Cambridge MA, US
Xinyuan Wu - Newton MA, US
Qingyi Li - Somerville MA, US
Iwona Wrona - Sharon MA, US
Andrew J. Jackson - Waltham MA, US
Bertrand L. Chenard - Waterford CT, US
Christopher M. Liu - Somerville MA, US
Guohua Liang - Acton MA, US
Matthew F. Baevsky - Northborough MA, US
Richard A. Earl - Westford MA, US
Lisa Mcqueen - Phoenixville PA, US
Jared Smit - Lafayette IN, US
Brett A. Cowans - Lafayette IN, US
International Classification:

C07D 473/08
Abstract:

The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).

Inhibiting The Transient Receptor Potential A1 Ion Channel
view source
US Patent:

20170050966, Feb 23, 2017
Filed:

Apr 23, 2015
Appl. No.:

15/305892
Inventors:

- Cambridge MA, US
Xinyuan Wu - Newton MA, US
Qingyi Li - Somerville MA, US
Iwona Wrona - Sharon MA, US
Andrew J. Jackson - Waltham MA, US
Bertrand L. Chenard - Waterford CT, US
Christopher Matthew Liu - Somerville MA, US
Guohua Liang - Acton MA, US
Matthew F. Baevsky - Northborough MA, US
Richard Alan Earl - Westford MA, US
Lisa Mcqueen - Phoenixville PA, US
Jared Smit - Lafayette IN, US
Brett A. Cowans - West Lafayette IN, US
International Classification:

C07D 473/08
Abstract:

The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).

Resumes

Director, Materials Science

view source

Location:

3609 Montclair St, West Lafayette, IN 47906

Industry:

Pharmaceuticals

Work:

Aptuit 1999 - Feb 2015
Director
Amri Ssci 1999 - Feb 2015
Director, Materials Science

Skills:

Drug Development
Pharmaceutical Industry
Gmp
Technology Transfer
Analytical Chemistry
Validation
Formulation
Spectroscopy
Drug Discovery
Glp
Sop
Uv/Vis